Skip to NavigationSkip to content

AZ ends Calquence trial early after Phase 3 success in chronic lymphocytic leukaemia

Published on 08/05/19 at 10:39am

AstraZeneca has unveiled new Phase 3 data on the efficacy of its Bruton tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) in the treatment of previously-treated patients with chronic lymphocytic leukaemia (CLL), demonstrating that the therapy “significantly increased the time patients live without disease progression” in interim analysis.

In the study, 310 participants were randomised into two groups, with one group receiving Calquence 100mg twice daily, and the second group receiving rituximab plus either Roche’s Mabthera (idelalisib) or Gilead’s Zydelig (bendamustine).

It was found that use of Calquence as a monotherapy led to statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) compared to the regimens administered in the second group.

As a result, AZ revealed that the Phase 3 study would end early, now that the drug has proven its efficacy in meeting the trial’s primary endpoint.  

“Calquence is the first BTK inhibitor to show benefit in a Phase 3 trial as a monotherapy compared to current standard-of-care combinations used in relapsed or refractory chronic lymphocytic leukaemia,” commented José Baselga, Executive Vice President, R&D Oncology at AZ. “We look forward to presenting detailed results at a forthcoming medical meeting.”

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches